Shah Preetam has filed 7 insider transactions across 2 companies since March 2024.
Most recent transaction: a grant/award of 47900 shares of Elicio Therapeutics, Inc. ($ELTX) on February 02, 2026.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Elicio Therapeutics, Inc. | $ELTX | Shah Preetam | See Remarks | A | Stock Option (Right to Buy) | 47900 | $0.00 | 47,900.0000 | 17,489,516 | 9999.99% | 0.27% |
| Feb. 2, 2026 | Elicio Therapeutics, Inc. | $ELTX | Shah Preetam | See Remarks | A | Common Stock | 24000 | $0.00 | 24,000.0000 | 17,489,516 | 9999.99% | 0.14% |
| April 15, 2025 | Elicio Therapeutics, Inc. | $ELTX | Shah Preetam | See Remarks | A | Stock Option (Right to Buy) | 191624 | $0.00 | 191,624.0000 | 15,953,524 | 9999.99% | 1.20% |
| Sept. 30, 2024 | Cidara Therapeutics, Inc. | $CDTX | Shah Preetam | Chief Financial Officer | A | Employee Stock Option (right to buy) | 130087 | $0.00 | 130,087.0000 | 0 | 9999.99% | 0.00% |
| March 15, 2024 | Cidara Therapeutics, Inc. | $CDTX | Shah Preetam | CFO & CBO | A | Employee Stock Option (right to buy) | 217500 | $0.00 | 217,500.0000 | 0 | 9999.99% | 0.00% |
| March 15, 2024 | Cidara Therapeutics, Inc. | $CDTX | Shah Preetam | CFO & CBO | A | Common Stock | 108750 | $0.00 | 335,960.0000 | 0 | 47.86% | 0.00% |
| March 11, 2024 | Cidara Therapeutics, Inc. | $CDTX | Shah Preetam | CFO & CBO | S | Common Stock | 18931 | $0.67 | 227,210.0000 | 0 | 7.69% | 0.00% |